| Objective: To quantitatively detect the content of endogenous cannabinoids in urine samples of patients with non-muscle-invasive bladder cancer(NMIBC)and healthy controls,and to verify the feasibility of endogenous cannabinoids such as arachidonic acid ethanolamine(AEA)and stearamide(SEA)as early non-invasive diagnostic markers for NMIBC,and to clarify the diagnostic performance.Methods: The urine samples of 21 patients with NMIBC diagnosed for the first time and 12 healthy control group who were hospitalized in Bethune Third Hospital of Jilin University from September 2021 to November 2022 were collected.All patients had no history of other malignant tumors,radiotherapy and chemotherapy and other benign diseases of the urinary system.Centrifuge the patient’s urine sample and use gradient elution to separate the substance to be tested;Use ESI ionization source to ionize the substance to be tested,and use high-performance liquid chromatography tandem mass spectrometry(HPLC-MS/MS)to quantitatively detect the content of AEA and SEA in urine.The sensitivity and specificity of the diagnostic model were evaluated using the subject working characteristic curve(ROC curve).Results: Compared with the healthy control group,the contents of AEA(P=0.0020<0.01)and SEA(P=0.0015<0.01)in urine samples of NMIBC patients were significantly higher,with significant statistical significance.The ROC curve was established and the urine AEA level of 0.113 ng/ml was selected as the cut-off value.AUC=0.8095,sensitivity 85.71%,specificity 66.67%;Select urine SEA level 0.304 ng/ml as the cut-off value.AUC=90.08%,sensitivity 90.48%,specificity 75.00%.Conclusion:1.The contents of AEA and SEA in urine of NMIBC patients were significantly higher than those of healthy control group;Urine AEA and SEA can be used as biomarkers for the diagnosis of NMIBC;2.The content of SEA in urine of NMIBC group and healthy control group is higher than that of AEA.It is easier to detect SEA as a potential diagnostic biomarker. |
PDF Full Text Request